HRAS and urothelial carcinoma: Accordingly, the present study aims to assess the efficacy of artemisinin as a prophylactic agent against early-stage urothelial carcinoma induced by BBN in male albino mice and to elucidate its underlying molecular mechanisms through modulation of critical oncogenes (FGFR3, HRAS) and the tumor suppressor gene TP53.